Home2018-07-27T04:33:28+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Digital Brochure

Two Page Fact Sheet

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

prescient therapeutics

LATEST NEWS

02/01/2020Board ChangePDF
23/12/2019PTX-200 High Overall Response in Ph2a Breast Cancer trialPDF
18/12/2019Release of Securities from EscrowPDF
12/12/2019Encouraging data from PTX-200 ovarian cancer trialPDF
27/11/2019Third complete response in PTX-200 AML TrialPDF